Raymond James & Associates’s BioLife Solutions BLFS Stock Holding History

Raymond James & Associates’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$3.51M	Buy	139,997 +5,803	+4%	+$137K	﹤0.01%	1881
2024 Q2	$2.88M	Buy	+134,194	New	+$2.6M	﹤0.01%	1939
2022 Q4	–	Sell	-15,923	Closed	-$362K	–	3933
2022 Q3	$362K	Sell	15,923 -60,940	-79%	-$1.3M	﹤0.01%	3060
2022 Q2	$1.06M	Buy	+76,863	New	+$1.13M	﹤0.01%	2395
2021 Q1	–	Sell	-5,927	Closed	-$236K	–	4005
2020 Q4	$236K	Buy	+5,927	New	+$202K	﹤0.01%	3275

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CRM

Cramer Rosenthal McGlynn Stamford, Connecticut $1.36B AUM 31.72% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Raymond James & Associates's BLFS Position: Q3 2024 in Review

Raymond James & Associates increased its BioLife Solutions (BLFS) stake by 4.3% in Q3 2024, buying an estimated $137K and bringing the position to 139,997 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

Raymond James & Associates first reported a position in BLFS in Q4 2020 and has held it in 5 quarters since. 195 funds tracked by Wall St. Rank hold BLFS as of Q3 2024.

Raymond James & Associates held 139,997 shares of BioLife Solutions worth $3.51M as of Q3 2024.
Raymond James & Associates bought 5,803 BioLife Solutions shares in Q3 2024, an estimated $137K.
BioLife Solutions made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1881 holding.
Raymond James & Associates first reported a position in BioLife Solutions in Q4 2020 and has held it in 5 quarters since.
195 funds tracked by Wall St. Rank held BioLife Solutions as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.